Get the Daily Brief

All action, no filler. BioBriefs delivers biotech’s 10 must-know updates, every morning.

Latest Biotech News

CRISPR and Gene Editing Innovations Propel Therapeutic Advances

October 01, 2025

The CRISPR gene editing field continues to expand rapidly with novel discoveries and companies capitalizing on recent breakthroughs like CASGEVY. New research elucidates the evolutionary origins...

Innovations in Cancer Immunotherapy and Radiotherapy Improve Patient Survival

October 01, 2025

Groundbreaking cancer research reveals promising strategies to enhance therapeutic efficacy and patient outcomes. Novel immunotherapeutic approaches, including glioblastoma-targeted biodegradable...

Pfizer and Trump Announce Most-Favored Nation Drug Pricing Deal and Launch Direct-to-Consumer Platform

October 01, 2025

Pfizer has become the first pharmaceutical company to agree to President Donald Trump's most-favored nation (MFN) drug pricing plan, which aims to lower U.S. drug prices to align with prices in...

Genmab to Acquire Merus for $8 Billion, Expanding Cancer Bispecific Antibody Pipeline

October 01, 2025

Danish biotech Genmab has agreed to acquire Dutch antibody company Merus for approximately $8 billion, a move that significantly enhances Genmab's oncology pipeline with the addition of...

Enanta Pharmaceuticals Pushes Forward with RSV Therapy Despite Phase 2b Setback

October 01, 2025

Enanta Pharmaceuticals reported that its oral RSV therapy, zelicapavir, narrowly missed the primary endpoint in a high-risk adult Phase 2b study but demonstrated positive signals in certain...

FDA Faces Operational Challenges Amid Government Shutdown Threat

October 01, 2025

The U.S. Food and Drug Administration (FDA) is bracing against the impact of a potential federal government shutdown as congressional negotiations stall. The shutdown threatens to furlough or...

Breakthroughs in Spatial Proteomics and High-Dimensional Molecular Analysis

October 01, 2025

New platforms for spatial proteomics and high-plex protein profiling are expanding the depth and resolution of in situ molecular analysis. Bruker’s GeoMx Discovery Proteome Atlas sets a new...

Cancer Treatment Advances: Novel Therapies and Biomarkers in Development

October 01, 2025

Cancer research continues to yield innovative therapeutic strategies and prognostic biomarkers. From the identification of dual gene overexpression (CDC20 and UBCH10) linked to poor head and neck...

CRISPR and Gene Editing Technologies Unlock New Mechanistic Insights

October 01, 2025

Recent studies have advanced understanding of CRISPR-Cas systems and epigenetic editing, enabling more durable gene silencing without permanent DNA alteration. Researchers discovered that...

AI and Machine Learning Enhance Biotech Research and Clinical Applications

October 01, 2025

Artificial intelligence and machine learning tools are catalyzing breakthroughs across medical diagnostics, drug discovery, and genomics. Cadence Molecular Sciences launched ROCS X, an AI-enabled...

Major Leadership and Corporate Moves Reshape Pharma and Biotech Sectors

October 01, 2025

Global pharmaceutical companies continue to undergo significant leadership changes and strategic restructurings. GSK announced the departure of CEO Emma Walmsley, marking the end of her nine-year...

Genmab Acquires Merus in $8 Billion Deal to Expand Cancer Pipeline

October 01, 2025

Genmab announced an $8 billion acquisition of Merus to gain full ownership of the latter's late-stage bispecific antibody, petosemtamab, targeting head and neck cancer. This acquisition aligns...

Pfizer's Drug Pricing Agreement Marks Industry Shift on Most-Favored Nation Model

October 01, 2025

Pfizer has become the first drugmaker to agree to implement a most-favored nation (MFN) pricing agreement, matching U.S. prices to comparable developed nations. The agreement includes launching a...

Revolution Medicines Hires Industry Veteran Sandler to Strengthen Leadership

October 01, 2025

Revolution Medicines has appointed a new executive with extensive experience at Mirati and ALX as part of their leadership expansion. This strategic hire strengthens the company's operational...

NRG Oncology Trials Show Advances in Cancer Radiation Therapy and Patient Outcomes

October 01, 2025

Recent NRG Oncology clinical trials have yielded significant findings across multiple cancer types. The NRG-BN001 trial demonstrated enhanced survival in glioblastoma patients treated with proton...

Machine Learning and AI Innovations Accelerate Molecular and Clinical Data Analysis

October 01, 2025

Advancements in artificial intelligence and machine learning are driving transformative tools in drug discovery and biomedical data analysis. Cadence Molecular Sciences launched ROCS X, an...

Innovative Cancer Immunotherapies and Antibody Drug Developments Emerge

October 01, 2025

Cutting-edge research reveals new immunotherapeutic strategies for challenging cancers. Climb Bio reported promising preclinical data for CLYM116, an anti-APRIL antibody showing deeper IgA...

Breakthroughs in DNA and RNA Technologies Accelerate Therapeutic and Diagnostic Research

October 01, 2025

Researchers are pioneering advanced nucleic acid technologies with impactful biotech applications. A novel massively parallel DNA synthesis system using microchip technology promises large-scale...

Novel Therapeutics Targeting Inflammatory and Metabolic Diseases Gain Momentum

October 01, 2025

Emerging therapies are tackling complex inflammatory and metabolic disorders with innovative approaches. Obefazimod, a selective miR-124 enhancer, shows clinical responses in ulcerative colitis...

Regulatory and Industry Leadership Changes Shape Biopharma Landscape

October 01, 2025

The biotech and pharmaceutical industry is witnessing important leadership transitions and regulatory evolutions. GSK announced Emma Walmsley’s departure as CEO, with Luke Miels set to succeed...